Guilford Street Laboratories raises £1.9m for AI-driven biomarker diagnostics

Precision diagnostics developer Guilford Street Laboratories has raised an estimated £1.9m to expand its AI-driven biomarker assay platform. This latest funding round values the Liverpool-based company at approximately £14.1m.

The company operates as a spin-out from University College London (UCL) and specializes in advanced biomarker assays and diagnostic solutions. It utilizes machine learning-driven mass spectrometry to deliver sensitive biomarker panels for the analysis of protein, lipid, and metabolite markers. These tools support pharmaceutical and biotechnology firms in drug discovery, clinical development, and patient care, with a focus on rare, cardiac, and neurodegenerative diseases.

Incorporated in 2023, Guilford Street Laboratories provides bespoke method development and serves as a contract research organization (CRO). Its technology is applied across early disease diagnosis, clinical trials, and personalized medicine. The firm also participates as a partner in EU Horizon consortiums.

This £1.9m investment follows a series of smaller funding tranches. In March 2025, the company completed six separate allotments totaling approximately £690k. Prior to that, in February 2024, it raised roughly £320k across four allotments. The current round is larger than these earlier seed-stage injections.

While the company's latest filed accounts list one employee, LinkedIn data indicates a team of 19 staff members. The business is headquartered in Liverpool and maintains its focus on multi-omics expertise to provide precision diagnostics for the global biotechnology sector. (Filing for this round was processed in April 2026, following an allotment in March 2026).